Tempus, founded in 2015, builds technology that uses data and artificial intelligence to make clinical and molecular data actionable for physicians, with a primary focus on oncology and life sciences. The company operates in the United States and connects to more than 65% of academic medical centers and over 50% of US oncologists, giving it significant reach across the clinical ecosystem.
Its technical work spans artificial intelligence, data science, clinical genomics, healthcare informatics, and platform engineering. Products include Tempus One, an AI-enabled clinical assistant; Lens, a data platform; and a suite of genomic sequencing assays. Together these tools aim to help physicians make more informed treatment decisions by integrating molecular profiling with clinical data.
The company describes its culture as one that optimizes impact over facetime and values collaboration over hierarchy. Its team includes experts from diverse backgrounds - among them cancer survivors, biologists, data scientists, and engineers - united by what it calls a relentless pursuit of better patient outcomes.
